**Supplemental Table 1. Treatment breakdown by race/ethnicity among patients with chronic HBV infection**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Overall Cohort** | **Total** | **Non-Hispanic White** | **African American** | **Hispanic** | **Asian** |  |
|  | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **P-Value** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Proportion Treatment Eligible** | 46.4 | 1,886 | 32.3 | 351 | 47.9 | 615 | 46.3 | 128 | 47.8 | 516 | <.0001 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Proportion Treated Among Treatment-Eligible** | 38.5 | 944 | 28.4 | 96 | 33.7 | 334 | 52.3 | 164 | 49.3 | 335 | <.0001 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Treatment Regimen** |  |  |  |  |  |  |  |  |  |  |  |
| Tenofovir alfenamide | 26.1 | 246 | 9.4 | 9 | 29.3 | 98 | 21.3 | 35 | 30.1 | 101 | <.0001 |
| Tenofovir disoproxil fumarate | 35.2 | 332 | 34.4 | 33 | 31.4 | 105 | 28.7 | 47 | 41.8 | 140 |  |
| Entecavir | 29.1 | 275 | 40.6 | 39 | 31.1 | 104 | 35.4 | 58 | 20.6 | 69 |  |
| Lamivudine | 1.3 | 12 | 3.1 | 3 | 1.2 | 4 | 1.2 | 2 | 0.9 | 3 |  |
| Other/Unknown | 8.4 | 79 | 12.5 | 12 | 6.9 | 23 | 13.4 | 22 | 6.6 | 22 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Propensity Score Matching Treated Cohort**  | **Total** | **Non-Hispanic White** | **African American** | **Hispanic** | **Asian** |  |
|  | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **P-Value** |
| **Treatment Regimen**  |  |  |  |  |  |  |  |  |  |  |  |
| Tenofovir alfenamide | 26.4 | 113 | 24.0 | 12 | 27.5 | 41 | 17.0 | 8 | 28.7 | 50 |  |
| Tenofovir disoproxil fumarate | 39.3 | 168 | 28.0 | 14 | 38.3 | 57 | 36.2 | 17 | 44.8 | 78 |  |
| Entecavir | 28.5 | 122 | 40.0 | 20 | 28.2 | 42 | 36.2 | 17 | 23.0 | 40 | <.0001 |
| Lamivudine | 1.9 | 8 | 2.0 | 1 | 2.0 | 3 | 4.3 | 2 | 1.1 | 2 |  |
| Other/Unknown | 4.0 | 17 | 6.0 | 3 | 4.0 | 6 | 6.4 | 3 | 2.3 | 4 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |